Topic:

M&A

Latest Headlines

Latest Headlines

After Walgreens avoids inversion, will Medtronic modify its Covidien offer?

Speculation is building that Minneapolis-based Medtronic will modify its offer for Dublin-based Covidien.

Should deal-needy Pfizer target antibiotics specialist Cubist?

Forget tax-advantaged Irish drugmakers. It may be a good time to take over an antibiotics maker on the cheap--and analysts have just the antibiotics maker in mind.

Novartis circles back with new terms for a stem cell biotech buyout--report

Novartis' on-again, off-again deal to buy out Israeli stem cell therapy developer Gamida Cell is reportedly back on again--though the pharma giant has apparently renegotiated the old $600 million pact to include a smaller upfront buy-in and one of its favored option agreements.

Are they or aren't they? Chugai spurns reports of Roche takeover talks

With M&A deals percolating around the global biopharma industry, investors bought in to the story anyway, driving up Chugai's stock price to record levels on the market buzz as fresh press reports added to the speculative frenzy.

Bloomberg: Roche negotiating for rest of Chugai for $10B

Just last month Roche CEO Severin Schwan indicated he wasn't interested in mega-deals to build his company, only smaller, more targeted buys. Of course what is targeted and what is mega is in the eyes of the beholder. The Swiss drugmaker is reportedly in talks to buy up the 40% piece of Japanese partner Chugai Pharmaceutical it doesn't currently own. Price? $10 billion.

Roche weighs a $10B deal for partner Chugai

Roche is taking a hard look at partner Chugai Pharmaceutical, according to a report, considering whether to pay about $10 billion to buy the remaining shares of the company.

Valeant, Pershing Square: Bring on the SEC insider trading probe

Go ahead and investigate Valeant and Pershing Square Capital Management, the drugmaker's deal partner in its $54 billion hostile bid for Allergan, the pair said Thursday in response to a reported SEC probe over insider trading. According to them, they've got nothing to hide.

InterMune takeover talk is tantalizing, but are investors too optimistic?

As InterMune awaits FDA approval for its drug to treat a rare lung disease, reports emerged Wednesday that it has hired financial advisers to weigh takeover bids from the likes of Sanofi and Roche.

Prefer a Swiss tax rate? Basilea chief says he's ready to parley

Basilea CEO Ronald Scott offered that the next best step for the biotech may be to just sell the Basel-based company to a U.S.-based biopharma company interested in a quick tax inversion deal that would allow a buyer the chance of trading American taxes for a sweeter deal in Switzerland.

Allergan bets up to $588M on Taris' bladder candidate

Amid its fight to stave off a hostile takeover, Botox maker Allergan is making a buy of its own, trading up to $587.5 million for a midstage bladder drug from the biotech Taris.